₦airaland Forum

Danger of investing in Biotech stocks, QTTB loosing 68% as a result of their failed clinical trials

Exit eyen at 26% and Closed @1% gain, mad market.

yok:
AI HAS BROUGHT BACK THE DOTCOM ERA
Looking at the market this morning, AI stocks are many in the early gainers list. So, one the best places we can put our money is AI insutrises. We have a watchlist for this. Also, the over 40% gain we are enjoying in one of our AI pick is like the base for the next rise in prices.

Wishing all happy trading/investing.

You are absolutely correct AI stocks on my watch list are doing the do, RR as done almost 100% Friday till today

If SAVA breaks the current level, it might head to 2.50

Penboy:
But why are you always having issues with the bots tho?

Just curious

Me don't know ooooo ,

aremso:
RR- watch entry at 0.50-0.60
KUKE - 0.30-0.33
ATAI - 1.30-1.40 long hold
CNSP -0.097-0.10 clinical trials results in the pipe line
MNTS - 0.50-0.53

HURA 5.50-5.80

Your DD applies

RR gradually moving by 16% currently

i posted something here around 4am but bot placed ban on me, have to use my second alnative account

i may be VERY WRONG but CNSP can do 50-200 percent if the expected trials is succesful and FDA approves

Foxo!

For those that asked about my stocks, if am to open new position the following stocks falls within my criteria

O T R K
LXEH

My entry will be 0.15-0.22, 0.35-0.40


DD applies
Am not currently in them as am holistically following my strategy

yok:
Good, you can post the criteria and then we can start sending our favorites tickers to the various Nigerian platforms. The foreign based platforms have no problem (average availble stock is over 6000- six thousand minimum). Here, Chaka is most affected. Chaka is a platform that is strong due to financial capacity/reputation/experience of the founders (they have been a SEC Nigeria Broker for ages!!!). So, you can see why some of us are endear to Chaka (longevity in stock broking business at least for the family of the Founder)
.So they have a name/reputation they can protect and guard jealousy.

I didn't save the details then

yok:
CHAKA SHOCKED ME WITH ONE OF THEIR BEST RESPONSES TO A CUSTOMER'S REQUEST
During the week CHAKA added on new ticker to their plaform!!!

It was done just because I asked for it (I have checked the ticker 0rior to making the request, it was not there. All I did was to tell them to add the ticker and I gave then the following details:

Ticker name: xxxxx
Approximate Market Capitalisation: $373million

And in less than 10 minutes I got a message that the ticker is now available on Chaka (they even sent me the screen shot).

I thought it was a joke (actually there are some thickers available in Chaka, but if you trade them , it will never be executed, like YINN or the inverse, SOXS, BSM), so I was thinking this may be those tickers that are available, but your trades may be REJECTED, so I put in my order, voala it was executed tge stock hit my account. Again, second day I bought the stock again.

So, if you have a favorite stock and you are on Chaka, just try and as for it. And if your request is turned down, let us ask the for the criteria they use in putting a ticker on their platform. For example a stock like GCT, is not there, but this stock is making waves in the market ( I did not border to ask, as with about 3 active alternatives, there is a limit we should push things).

Going forward into the new week, Monday may probably start on a bullish note, as the type of employment report on Friday favour's rate cut, and rate cut creates excitement for investors.

I think I asked for a ticket to be added on bamboo too but they sent me list of criteria it will meet before it can be added.

For those that hates RS let me share my mentee story, I told her to buy AKA as I mentioned it here last year. She bought around 0.........50 they did RS leaving the free float at 900k+ as at the time she screen shot her holding to me at 9 dolls she was on +85% now AKA is 25 so do the calculationd

Penboy:
192 what?

Capital YES came in with 442 which reduced to 193 or 192 I booked the loss and enter another one Ooooo ttttt rrr kkkk at 00000.....18 gave 1.066kunits pulled out at 0000..50 do the calculation account is for my friend and since she a busy person I took it from her since I was the one that introduced her to US stocks. I have bought 3.7k units of KTRA for total sum of 530 and am expecting 100% here so before you know it 192 has turned 1k

I wrote that way cos bot has taken my major account for now I don't know what it flagged. Very doable have watched guys in US turned 1.5k to over 1m with time all I needed to do is to study how they achieved that and follow their patterns

Born2conquer:
I lost 15k dollars to ev sector. Hoping they would at least recover a bit for me to pull out

Wow 15k? Hmmm that is much ooo. I entered mulin then I did not stay long oo I pulled out maybe with 20 dollars loss entered FFIE and FSRN I quickly pulled out. Once I noticed it hard for it to brake out and when brake out it doesn't sustain it and no catalyst to push up again I don Japa be that ooo. Anyway with right strategies you will recover and double up on profits

Never forget you can achieve ANYTHING in life as long as you're dedicated/patient enough.
Happy Sunday

Lexusgs430:
I sold my tesla shares at $240...... Thinking of reentering, but the near collapse of the EV sector is my worry......

This is the best time to buy an electrical vehicle, but not EV shares....... 😁😁

All the EV stocks are seriously in red and some will soon go to ICU

Lexusgs430:
Tesla never pays dividends..... Tesla simply reinvests profit (after Elon creams off $56Billion)..... 🤣😜

Wow very funny and some have been holding since have started monitoring it towards the end of last year at 244 now 147 almost 50% gone. Anyway, just asking as am not even interested in any stock above penny for now. Once I hit my 20-100% or 300-400% as the case may be I don Japa be that

This is the catalyst am waiting for!



MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced it has formalized its collaboration with KR8.ai Inc. (“KR8”) and secured the exclusive license to KR8’s AI-based software to support the development and commercial launch of its new health and wellness offering - the VITHAR™ AI Health Coach. As previously announced, the Company is in the process of launching its new subscription-based, direct-to-consumer product offering that is designed to provide personalized health and wellness recommendations, by combining: (i) FOXO’s machine learning models to analyze epigenetic biomarkers; (ii) the Company’s expertise and algorithms correlating epigenetic analysis with health outcomes; and (iii) published, peer-reviewed, clinical data and other verified, third-party health resources.

Mark White, Interim CEO of FOXO Technologies, stated, “Formalization of this agreement is an important milestone as we advance our new direct-to-consumer offering. By leveraging our epigenetic data, genetic insight and growing patent estate, with KR8’s AI-driven analytic software and proprietary algorithms, we aim to provide the most robust direct-to-consumer health and wellness app in the industry. We believe this offering will provide consumers with unparalleled insight, including a comprehensive risk analysis and actionable health insights to understand their biological age, as well as optimize and better manage their health. Our goal is to quickly and cost-effectively capture a meaningful share of the Health and Fitness App Market size, which was valued at $8.2 billion in 2022 and is projected to reach $35.7 billion by 2030 (Verified Market Research) through an offering that goes way beyond traditional health apps, coupled with a cost-effective go-to-market strategy. The new app will simply require users to send a saliva or blood sample, and the technology will then combine this information with user health stats, as well as peer-reviewed clinical studies and other verified health resources to provide customized AI-driven health recommendations. Since initially announcing the collaboration, we have made tremendous progress and are well ahead of schedule with our planned commercial launch. We could not be more excited about the outlook for VITHAR™ and look forward to providing further updates.”

About KR8.ai
KR8.ai harnesses the power of AI-driven analytics to optimize social media accounts’ current performance against their full potential. Their premier mobile application, aptly named 'the KR8 Coach', provides a comprehensive evaluation of an account’s current performance against their full potential. Based on this analysis, it then offers intelligent, AI-derived suggestions to amplify the reach and effectiveness of their posts. Beyond this, KR8 AI's innovative solutions are adaptable and can seamlessly be integrated into third-party, direct-to-consumer applications. This adaptability not only streamlines processes but also results in more economically efficient technology implementations.

About FOXO Technologies Inc. (“FOXO”)
FOXO, a technology platform company, is a leader in epigenetic biomarker discovery and commercialization focused on commercializing longevity science through products and services that serve multiple industries. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. For more information about FOXO, visit www.foxotechnologies.com. For investor information and updates, visit https://foxotechnologies.com/investors/.

Forward-Looking Statements
This press release contains certain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of FOXO, market size and growth opportunities, competitive position, and technological and market trends, are forward-looking statements. Such forward-looking statements include, but not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding FOXO; the future financial condition and performance of FOXO and the products and markets and expected future performance and market opportunities of FOXO. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “could,” “expect,” “estimate,” “future,” “intend,” “strategy,” “may,” “might,” “strategy,” “opportunity,” “plan,” project,” “possible,” “potential,” “project,” “predict,” “scales,” “representative of,” “valuation,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the risk of changes in the competitive and highly regulated industries in which FOXO operates, variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; (ii) the ability to implement FOXO’s business plans, forecasts, and other expectations; (iii) the ability to obtain financing if needed; (iv) the ability to maintain its NYSE American listing; (v) the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; (vi) potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans; (vii) the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and (viii) the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO’s prospective customers operate. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Ll
Contacts
Crescendo Communications, LLC
(212) 671-1020
foxo@crescendo-ir.com


FOXO TECHNOLOGIES INC.
NYSEAM:FOXO View stock quote and chart View SEC Filings
More News

For dividend hunting NAT currently have support at 3.7 and 3.6 and if it brakes that level going to 2.80 if it brakes that too going to 2.50-1.80. at 2-1.80 na mad discount be that.



DD applies

Aremsssoo:
For those who get liver for KTRA, it will soon take off. Has a strong coconut head at 0.10 not allowing pushing buy shorties again so it closed at 2.70% gain normal hrs and after hrs it gained 12%. It will take off any time and they can push to around 0.20-0.50 before RS for merger. If u hate RS pls stay off this stock but am optimistic at least 100% gain sure here.

DD applies.

Finally sailing off

Those holding Tesla, are they paying dividend?

For those who get liver for KTRA, it will soon take off. Has a strong coconut head at 0.10 not allowing pushing buy shorties again so it closed at 2.70% gain normal hrs and after hrs it gained 12%. It will take off any time and they can push to around 0.20-0.50 before RS for merger. If u hate RS pls stay off this stock but am optimistic at least 100% gain sure here.

DD applies.

Capitas7:
Oga Aremso, please share the name when the time comes and you are comfortable to do so. Some of us can learn from your pick, and even make money from it.

Sure I will post my pick here, some had made money on them here

Bot don hold my first account again oo

I read some back and forth post here, my final take and advice is to put in more efforts if we don't want to subscribe to anyone. If we know what we are doing and put in required effects, we shall surely be rewarded adequately.